{"paper_id":"46bd0076-24be-4703-93ae-d0d0a66c0528","body_text":"Letrozole plus metformin versus letrozole alone in the treatment of symptomatic endometrioma\nDOI:\nhttps://doi.org/10.18203/2320-1770.ijrcog20252315Keywords:\nLetrozole, Metformin, EndometriomaAbstract\nBackground: Endometriosis is a chronic, estrogen-dependent inflammatory disorder affecting up to 10% of reproductive-age women, with endometrioma present in 17-44% of cases and linked to pain and subfertility. This study aims to compare the efficacy of letrozole plus metformin versus letrozole alone in the treatment of women with symptomatic endometrioma. The aim of the study was to evaluate the efficacy of letrozole plus metformin versus letrozole alone in reducing endometrioma size, pain, and serum IL-6 levels, with comparable side effects.\nMethods: This randomized controlled trial (RCT) was conducted at the department of reproductive endocrinology and infertility, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka (January 2022 to June 2023). Fifty women with endometrioma (<5 cm) received either letrozole (2.5 mg/day) plus metformin (1500 mg/day) or letrozole alone for 12 weeks. Outcomes (endometrioma size, visual analog scale (VAS) pain score, IL-6 levels) were analyzed using SPSSv23 (paired/unpaired t tests; p<0.05 significant).\nResults: Letrozole plus metformin (Group A) and letrozole alone (Group B) were compared in 50 women with endometrioma, with no significant baseline differences (p>0.05). After 3 months, group A showed greater reduction in endometrioma size (p=0.003), pain scores, and IL-6 levels, though the latter two were not statistically different between groups (p>0.05). Side effects were mild and similar in both groups, indicating improved efficacy of the combination therapy with comparable safety.\nConclusions: Combined letrozole and metformin therapy significantly reduces endometrioma size, pain, and IL-6 levels more than letrozole alone, offering a promising treatment for endometriosis patients seeking fertility.\nMetrics\nReferences\nVercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nature Rev Endocrinol. 2014;10(5):261-75. DOI: https://doi.org/10.1038/nrendo.2013.255\nKhine YM, Taniguchi F, Harada T. Clinical management of endometriosis-associated infertility. Reproduct Med Biol. 2016;15(4):217-25. DOI: https://doi.org/10.1007/s12522-016-0237-9\nHamid AM, Madkour WA, Moawad A, Elzaher MA, Roberts MP. Does cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study. Arch Gynecol Obst. 2014;290(4):677-82. DOI: https://doi.org/10.1007/s00404-014-3242-4\nAlborzi S, Keramati P, Younesi M, Samsami A, Dadras N. RETRACTED: The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas. Fertil Steril. 2014;101(2):427-34. DOI: https://doi.org/10.1016/j.fertnstert.2013.10.019\nFerrero S, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reproduct Biol Endocrinol. 2011;9:88. DOI: https://doi.org/10.1186/1477-7827-9-88\nGurates B, Bulun SE. Endometriosis: the ultimate hormonal disease. Semin Reprod Med. 2003;21(02):125-34. DOI: https://doi.org/10.1055/s-2003-41319\nZeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, et al. Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17β-estradiol. J Clin Endocrinol Metabol. 1998;83(12):4474-80. DOI: https://doi.org/10.1210/jc.83.12.4474\nAkoum A, Lemay A, Paradis I, Rheault N, Maheux R. Endometriosis: Secretion of interleukin-6 by human endometriotic cells and regulation by proinflammatory cytokines and sex steroids. Hum Reprod. 1996;11(10):2269-75. DOI: https://doi.org/10.1093/oxfordjournals.humrep.a019088\nVelazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43(5):647-54. DOI: https://doi.org/10.1016/0026-0495(94)90209-7\nBurney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511-9. DOI: https://doi.org/10.1016/j.fertnstert.2012.06.029\nCarvalho L, Podgaec S, Bellodi-Privato M, Falcone T, Abrão MS. Role of eutopic endometrium in pelvic endometriosis. J Mini Inv Gynecol. 2011;18(4):419-27. DOI: https://doi.org/10.1016/j.jmig.2011.03.009\nAttar E, Tokunaga H, Imir G, Yilmaz MB, Redwine D, Putman M, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metabol. 2009;94(2):623-31. DOI: https://doi.org/10.1210/jc.2008-1180\nMadny EH. Efficacy of letrozole in treatment of endometriosis-related pain. Middle East Fertil Society J. 2014;19(1):64-8. DOI: https://doi.org/10.1016/j.mefs.2013.04.007\nAmir M, Ishrat S, Nasrin I, Halder S, Rahman F, Hossain MRZ. Letrozole versus dienogest in endometrioma recurrent after surgery: a randomized controlled trial. Int J Reprod Contracept Obstet Gynecol. 2022;11(10):2715-22. DOI: https://doi.org/10.18203/2320-1770.ijrcog20222371\nLord J, Wilkin T. Metformin in polycystic ovary syndrome. Curr Opin Obstetr Gynecol. 2004;16(6):481-6. DOI: https://doi.org/10.1097/00001703-200412000-00008\nBruun JM, Pedersen SB, Richelsen B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Hormone Metab Res. 2000;32(11/12):537-41. DOI: https://doi.org/10.1055/s-2007-978682\nMansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003;79(4):956-62. DOI: https://doi.org/10.1016/S0015-0282(02)04925-7\nYilmaz B, Sucak A, Kilic S, Aksakal O, Aksoy Y, Lortlar N, et al. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstetr Gynecol. 2010;202(4):368-e1. DOI: https://doi.org/10.1016/j.ajog.2009.10.873\nZhou Y, Xu JN, Zeng C, Li X, Zhou YF, Qi Y, Xue Q. Metformin suppresses prostaglandin E2-induced cytochrome P450 aromatase gene expression and activity via stimulation of AMP-activated protein kinase in human endometriotic stromal cells. Reprod Sci. 2015;22(9):1162-70. DOI: https://doi.org/10.1177/1933719115590664\nFoda AA, Aal IA. Metformin as a new therapy for endometriosis, its effects on both clinical picture and cytokines profile. Middle East Fertil Society J. 2012;17(4):262-7. DOI: https://doi.org/10.1016/j.mefs.2012.09.001\nTakemura Y, Osuga Y, Yoshino O, Hasegawa A, Hirata T, Hirota Y, et al. Metformin suppresses interleukin (IL)-1β-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab. 2007;92(8):3213-8. DOI: https://doi.org/10.1210/jc.2006-2486\nAnsary SA, Ishrat S, Banu J, Fatima P, Nasreen F, Jahan I, et al. Evaluation of the effect of aromatase inhibitor in reducing the size of endometrioma. Int J Reprod Contracept Obstet Gynecol. 2021;10:1295-302. DOI: https://doi.org/10.18203/2320-1770.ijrcog20211103\nOner G, Ozcelik B, Ozgun MT, Serin IS, Ozturk F, Basbug M. The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum Reproduct. 2010;25(4):932-7. DOI: https://doi.org/10.1093/humrep/deq016\nJamali N, Zal F, Mostafavi-Pour Z, Samare-Najaf M, Poordast T, Dehghanian A. Ameliorative effects of quercetin and metformin and their combination against experimental endometriosis in rats. Reprod Sci. 2021;28:683-92. DOI: https://doi.org/10.1007/s43032-020-00377-2\nVallée A, Vallée JN, Le Blanche A, Lecarpentier Y. PPARγ agonists: emergent therapy in endometriosis. Pharmaceuticals. 2021;14(6):543. DOI: https://doi.org/10.3390/ph14060543\nAmsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005;84(2):300-4. DOI: https://doi.org/10.1016/j.fertnstert.2005.02.018\nAttar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril. 2006;85(5):1307-18. DOI: https://doi.org/10.1016/j.fertnstert.2005.09.064","source_license":"CC0","license_restricted":false}